Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026
Company Drug

Amoytop Biotech’s Peginterferon α-2b Receives NMPA Approval for Primary Thrombocytosis Clinical Trial

Fineline Cube Jul 8, 2024

Amoytop Biotech Co. Ltd (SHA: 688278), based in Xiamen, has announced that it has received...

Company Drug

Daiichi Sanky’s Mirogabalin Gets Green Light from China for Diabetic Neuropathic Pain

Fineline Cube Jul 8, 2024

Daiichi Sanky (TYO: 4568), a pharmaceutical company based in Japan, has announced that it has...

Company Drug

Antengene’s Xpovio Secures NMPA Approval for R/R Diffuse Large B-Cell Lymphoma

Fineline Cube Jul 8, 2024

Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it...

Company Drug

Sirnaomics’ STP122G Achieves Phase I Milestone with Positive Interim Data for Anticoagulation Treatment

Fineline Cube Jul 8, 2024

Sirnaomics Ltd (HKG: 2257) has announced the completion of the Phase I second sequence for...

Company Deals

Kindstar Global and MGI Tech Co., Ltd. Form Partnership to Establish Multi-Omics Service Center in China

Fineline Cube Jul 8, 2024

Kindstar Global (HKG: 9960), a biopharmaceutical company based in China, has announced a strategic partnership...

Company Legal / IP

Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer

Fineline Cube Jul 8, 2024

Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...

Company Drug

Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted

Fineline Cube Jul 8, 2024

Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a...

Company Drug

Medigene AG Secures Chinese Patent for TCR-T Therapy Targeting NY-ESO-1 and LAGE 1a

Fineline Cube Jul 8, 2024

Medigene AG (ETR: MDG1), a biopharmaceutical company based in Germany, has announced that it has...

Company

MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth

Fineline Cube Jul 5, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai...

Company Deals

Singlera Genomics Secures Over RMB 100 Million in Strategic Financing to Boost R&D and Commercialization

Fineline Cube Jul 5, 2024

Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego,...

Company Drug

Doma Biopharmaceutical’s Bispecific ADC DM001 Receives FDA Clearance for Clinical Trial

Fineline Cube Jul 5, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-9813 IPF Clinical Trial

Fineline Cube Jul 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management

Fineline Cube Jul 5, 2024

Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...

Company Drug R&D

Semaglutide Use Linked to Rare Eye Condition NAION in New Study

Fineline Cube Jul 5, 2024

A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...

Company Drug

J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients

Fineline Cube Jul 5, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...

Company Drug

Sanofi’s RSV Preventative Therapy Beyfortus Launches in China

Fineline Cube Jul 4, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus...

Company Deals

Genertec and CTHG Fund Invest in Neusoft Medical Systems to Boost Medical Imaging

Fineline Cube Jul 4, 2024

China General Technology (Group) Holding Co Ltd, commonly referred to as Genertec, has announced plans...

Company Deals

Guangzhou Pluslife Partners with Gates Foundation to Combat STIs in Low-Income Countries

Fineline Cube Jul 4, 2024

Guangzhou Pluslife Technology Co., Ltd, a specialist in Point-Of-Care Testing (POCT) based in China, has...

Company Deals

United Imaging Healthcare to Launch Financial Leasing Arm with RMB 450 Million Investment

Fineline Cube Jul 4, 2024

United Imaging Healthcare (UIH, SHA: 688271), a leading medical equipment company based in Shanghai, has...

Company Deals

Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda

Fineline Cube Jul 4, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Posts pagination

1 … 369 370 371 … 700

Recent updates

  • HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases
  • Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals
  • China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio
  • Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy
  • CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Company

Antengene Achieves Profitability with H1 2026 Revenue of RMB 490-536M Driven by Strategic Out-Licensing Deals

Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Company Medical Device

Broncus Medical’s BroncTru Dilation Catheter Secures CE Mark Under EU MDR for Comprehensive Lung Diagnostics and Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.